Competing interests: BP has received grants from Tesaro/GSK, Merck, Astra Zeneca, Karyopharm Therapeutics, Incyte, Toray, VBL Therapeutics, InxMed, Agenus, Clovis Oncology, Roche/Genentech, Mersana, Celsion/Immunon, I-Mab, Takeda, Onconova, Celgene, Sutro Biopharma, Novocure, Seagen, NRG Oncology, Duality Bio, Xencor, Immunogen, Eisai, Acrivon, and Alkermes; consulting fees from Tesaro/GSK, Astra Zeneca, Merck, Immunogen, GOG Foundation, Seagen, Lilly, Eisai, Signatera, Celsion, Sutro Biopharma, Imvax, Incyte, InxMed, Onconova Therapeutics, R-Pharm, Regeneron, and Duality Bio; honoraria from Bioascend, PERS, Vanium, Curio, OncLive, Yale University, and PeerView; support for attending meetings and/or travel from GOG Partners; participated on data safety monitoring boards (DSMBs) or advisory boards for Sutro Biopharma, Astra Zeneca, GOG Foundation, Celsion/Immunon, Toray, InxMed, Onconova, Imvaz, I-Mab, Tesaro/GSK, Merck, Mersana, Nuvation, and BioNTech; and served as SGO Clinical Practice Committee Chair, SGO Board of Directors, SGO COVID-19 Taskforce Co-chair, GOG Partners, and NYOB Society Second Vice President. PT has received grants (paid to the institution) from Merck and GSK; participated on DSMBs or advisory boards for Iovance, Astra Zeneca, Verastem, GSK, Seagen, Immunon, Immunogen, Mersana, Novocure, Zentalis, Caris, and Merck; and holds stock or stock options in Immunon. AM has received honoraria and travel fees from Foundation for Women’s Cancer and served as President of Endometrial Cancer Action Network for African Americans. KM has received consulting fees from Eisai. DC has received honoraria from Antibacterial Resistance Leadership Group (ARLG); grants from Duke University for COMET study (cancer) Patient Leadership Group, UCSF for STORMing Cancer Patient Advocate Team, and MD Anderson for PRECISION Patient Advisory Involvement Panel; consulting fees from SimBioSys, MaxisHealth, Health Literacy Media (HLM; as Patient Advisor), Apellis Pharmaceuticals, and Kinnate Biopharma; honoraria and travel support from HMP Education; support for travel from Agile Falcon Strategic Group, DGE Events, and Informa; participated on DSMBs for American Society for Clinical Oncology and on Patient Partner Council for Evidera; has a role on Executive Group for Metastatic Breast Cancer Alliance and a role as committee member for Alliance for Clinical Trials in Oncology; and received manuscript writing support from IQVIA through Regeneron. KL has received fees for participation on advisory boards for Astra Zeneca, Merck, and Eisai. MCM is an employee and stockholder of Incyte. BS has received consulting fees from Astra Zeneca, Clovis, GSK, Genentech, Lilly, Novartis, Gilead, Seagen, Karyopharm, Addy, Circulogene, GOG Foundation, Merck, Imvax, EQRx, and Nuvation; and honoraria from Seagen.